Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 16, 2012Clinical Study Seeks to Evaluate MORAb-004 plus best supportive care for Extending Progression-Free Survival of Patients with Chemorefractory Metastatic Colorectal Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of...
-
Mar 27, 2012Morphotek®, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian CancerClinical Study Seeks to Evaluate Farletuzumab in Combination with Standard of Care in First-Relapse Patients with Platinum-Sensitive Ovarian Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today it has completed enrollment of the FAR-131 clinical trial. The study is a pivotal Phase 3...
-
Mar 7, 2012
Woodcliff Lake, NJ, March 6, 2012 - Eisai Inc. today announced that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New...
-
Feb 10, 2012
On February 9, 2012, the U.S. Food and Drug Administration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one abstention that the data in the company's...
-
Jan 9, 2012
Exton, PA, January 9, 2012 -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into two agreements with Fox Chase Cancer Center ("Fox Chase") in Philadelphia, PA...